Mpox Today 2023
Mpox Today 2023
MpoxToday publishes information people can trust to make informed decisions regarding Mpox virus (MPXV) prevention, treatment, and vaccination.
On May 11, 2023, the WHO announced it officially ended its public health emergency of international concern declaration.
"Mpox has not been eliminated, and modeling studies suggest that a resurgence is a possibility this summer," according to May 9, 2023, Quick Take report from the O'Neill Institute for National and Global Health Law and amfAR, the Foundation for AIDS Research.
The WHO EURO published a technical update #25 on Mpox considerations on April 25, 2023, and the Lancet Infectious Disease published an editorial on April 6, 2023, revealing Mox vaccine breakthrough cases. And the U.S. Centers for Disease Control and Prevention (CDC) published the Risk Assessment of Mpox Resurgence and Vaccination Considerations on April 4, 2023. Furthermore, the CDC recently confirmed over 111 countries had reported about 86,000 Mpox patients and 88 related fatalities since May 2022.
Treatments: Pre-exposure prophylaxis and post-exposure prophylaxis Mpox treatments are authorized. This April 2023 review highlights possible therapeutic options (e.g., tecovirimat, brincidofovir, cidofovir) for managing human poxvirus infections.
Testing: Diagnostic laboratories offer a variety of tests to identify the infectious status and Mpox virus types.
Research: Unbiased, peer-reviewed clinical research that offers insights into Mpox science.
Disease: Mpox is part of the same family of viruses as the variola virus that causes smallpox.
Mpox Information Sources
Mpox Today's information sources include the WHO, the U.S. CDC, U.S. FDA, European Medicines Agency, and the U.K. Health Services Agency, research publications, academic institutions, and industry participants. Information from these world-class enterprises is aggregated and curated for mobile readership into a language people can understand and trust.